Barclays analyst Etzer Darout initiated coverage of Janux Therapeutics (JANX) with an Overweight rating and $47 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Synopsys downgraded, Oracle upgraded: Wall Street’s top analyst calls
- Janux Therapeutics initiated with a Buy at Truist
- Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic Advancements
- Janux Therapeutics resumed with a Buy at Stifel
- Janux Therapeutics initiated with a Buy at Guggenheim